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The mechanism by which respiratory syncytial virus (RSV) suppresses T-cell proliferation to itself and other
antigens is poorly understood. We used monocyte-derived dendritic cells (MDDC) and CD4 T cells and
measured [3H]thymidine incorporation to determine the factors responsible for RSV-induced T-cell suppres-
sion. These two cell types were sufficient for RSV-induced suppression of T-cell proliferation in response to
cytomegalovirus or Staphylococcus enterotoxin B. Suppressive activity was transferable with supernatants from
RSV-infected MDDC and was not due to transfer of live virus or RSV F (fusion) protein. Supernatants from
RSV-infected MDDC, but not MDDC exposed to UV-killed RSV or mock conditions, contained alpha interferon
(IFN-; median, 43 pg/ml) and IFN- (approximately 1 to 20 ng/ml). Neutralization of IFN- with monoclonal
antibody (MAb) against one of its receptor chains, IFNAR2, or of IFN- with MAb against either of its receptor
chains, IFN-R1 (interleukin 28R [IL-28R]) or IL-10R2, had a modest effect. In contrast, blocking the two
receptors together markedly reduced or completely blocked the RSV-induced suppression of CD4 T-cell
proliferation. Defining the mechanism of RSV-induced suppression may guide vaccine design and provide
insight into previously uncharacterized human T-cell responses and activities of interferons.
Respiratory syncytial virus (RSV) is a member of the
Paramyxoviridae family of negative-strand RNA viruses that
includes parainfluenza virus 1 (PIV1), PIV3, mumps, and mea-
sles, as well as newly recognized pathogens such as metapneu-
movirus, Nipa virus, and Hendra virus. RSV is often the first
pathogen encountered by infants and accounts for about 24%
of hospitalizations for pediatric respiratory tract disease. RSV
is the primary cause of infantile pneumonia and bronchiolitis,
the latter being an obstructive disease characterized by wheez-
ing and hypoxia due to necrosis of the respiratory epithelium
and airway plugging (9, 14, 22, 33). Severe infantile RSV-
induced lower respiratory infections (LRI) may herald the
onset of allergic diseases and/or asthma later in life (57). While
RSV-induced LRI beyond age 3 are uncommon, RSV is a
known trigger for wheezing in older asthmatics, and frequent
upper respiratory infections in children and adults are com-
mon. Finally, RSV is a significant cause of morbidity in the
elderly and mortality in bone marrow transplant recipients (22).
Among Paramyxoviridae family members, RSV, PIV3, and
measles are known to suppress T-cell responses to secondary
antigenic stimuli (43, 45, 50, 55). Clinical immunosuppression
is a common complication of measles, and secondary bacterial
and viral infections contribute to its high morbidity and mor-
tality (6). The mechanism by which measles suppresses T-cell
responses is not clear, but altered cytokine expression and
impaired antigen presentation have been implicated (for re-
views, see references 35 and 50). PIV3 is also immunosuppres-
sive, perhaps a consequence of increased expression of inter-
leulin-10 (IL-10) (54, 55).
Suppression of in vitro T-cell responses by human RSV (43,
46) and bovine RSV has been described (26, 51, 52). Unlike
measles, however, it is not immediately obvious that suppres-
sion of T-cell responses in vitro is clinically relevant. It is quite
possible that this immunosuppressive activity contributes to
the phenomena of repeat infections with RSV, despite a lim-
ited number of subtypes and a genome that is not prone to
mutation, as is, for example, influenza. In addition, secondary
infection with Pasteurella haemolytica is not rare in bovine
RSV-infected sheep and goats (10), and Streptococcus pneu-
moniae may complicate human RSV LRI more commonly
than has been appreciated (30). Furthermore, immunosup-
pression may be mechanistically linked to a bias toward re-
sponses dominated by Th2 cytokines such as IL-4 and IL-13
induced by early infection with RSV in animal models (15).
This effect may in turn contribute to subsequent episodes of
wheezing in childhood with repeat exposure to this virus and
may also cause predisposition to the development of asthma
and allergic diseases.
The mechanism by which RSV suppresses T-cell responses
is not well understood. Contact-dependent mechanisms (49),
IL-1 receptor antagonist (IL-1RA) (32, 46), and alpha inter-
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feron (IFN-) (42) have each been implicated but inconclu-
sively so. The implication that IFN- is immunosuppressive is
somewhat paradoxical, since it is well documented that the
nonstructural genes of RSV, NS1 and NS2, also decrease ex-
pression of the cellular responses to type I IFN (IFN- and -)
(47, 48, 58).
To date, T-cell responses to RSV have been studied using
peripheral blood mononuclear cells, which is a heterogeneous
population. This may have impeded efforts to define the mech-
anisms of RSV-induced immunosuppression. Therefore, we
first designed a simplified experimental system using only
monocyte-derived dendritic cells (MDDC) and autologous
CD4 T cells and then focused on identifying soluble factors
expressed by MDDC in response to RSV that suppress T-cell
proliferation to the superantigen Staphylococcus enterotoxin B
(SEB).
MATERIALS AND METHODS
Cell culture. Human MDDC were generated from elutriated monocytes ob-
tained from healthy adult donors (65 years of age) at the National Institutes of
Health (NIH) Clinical Center blood bank. The monocytes were cultured at 3 
105/ml in RPMI medium with 1% nonessential amino acids and 1% sodium
pyruvate (Biosource, Rockville, MD), 10% fetal bovine serum (HyClone, Logan,
UT), 0.05 mM -mercaptoethanol (Sigma, St. Louis, MO), 20 g/ml gentamicin
(Invitrogen, Grand Island, NY), 800 U/ml recombinant human granulocyte-
macrophage colony-stimulating factor (Leukine; Immunex, Seattle, WA), and
500 U/ml recombinant human IL-4 (rhIL-4; BD Pharmingen, San Diego, CA) for
7 days.
Elutriated lymphocytes were purified with Ficoll-Hypaque density centrifuga-
tion (Sigma) and frozen in liquid nitrogen. After thawing and overnight incuba-
tion, CD4 T cells were purified from the lymphocytes by positive selection with
a magnetic column and beads (AutoMACS; Miltenyi Biotec, Auburn, CA) ac-
cording to the manufacturer’s protocol, and purity was verified by flow cytometry.
The Institutional Review Boards of the NIH and at the U.S. Food and Drug
Administration approved the study.
Monoclonal antibodies and recombinant cytokines. Mouse anti-IFN-/ re-
ceptor chain 2 (IFNAR2, CD118) monoclonal antibody (MAb) was purchased
from PBL laboratory (Piscataway, NJ). Anti-IL-10R2 MAb and mouse immu-
noglobulin G2a (IgG2a) and IgG1 isotype controls were obtained from R & D
systems (Minneapolis, MN). The humanized MAbs palivizumab and omali-
zumab were obtained from Medimmune (Gaithersburg, MD) and Genentech
(San Francisco, CA), respectively. Anti-IL28R was generated as previously de-
scribed (19).
Viral infection of MDDC. PIV3 was propagated at 32°C in LLC-MK2 cells or
Vero cells, as previously described (23). The Udorn strain of influenza A virus
(A/Udorn/72) was propagated in HEp-2 cells in the presence of 7.5 g of
trypsin/ml as previously described (62). The wild-type A2 strain of RSV and
recombinant RSV expressing green fluorescent protein (rgRSV) (24) were
grown in HEp-2 cells (14). Wild-type RSV was further purified by centrifugation
through a sucrose gradient to eliminate cytokine contaminants (58). Virus con-
centrations were determined by plaque assay (28). RSV was inactivated with UV
light (UV-RSV) in a Stratalinker UV cross-linker for 10 min (0.12 J/cm2; Strat-
agene, La Jolla, CA). Complete inactivation of RSV was confirmed by plaque
assay. Cytomegalovirus (CMV) grade 2 antigen was purchased from Microbix
Biosystems (Toronto, Ontario).
MDDC (1  106/ml) were exposed to virus for 4 h at 37°C and, when stated,
washed extensively in culture medium to remove any nonadherent virus prior to
coculture with lymphocytes or CD4 T cells. MDDC supernatants were collected
after overnight culture of infected and washed MDDC. Mock-infected MDDC
were exposed to sucrose solutions of a concentration equal to those in the viral
stocks as measured by the invertase-hexokinase-G6PD assay (Sigma). Infection
of MDDC with rgRSV was verified with an Olympus BX41 (Tokyo, Japan)
fluorescent microscope and digitally photographed with the Spot RT Color
system (Sterling Heights, MI).
Cell stimulation and in vitro proliferation assay. Virus-exposed MDDC were
cultured with lymphocytes at a ratio of 1:10 or with CD4 T cells at a ratio
adjusted according to the percentage of CD4 T cells in lymphocytes of that
donor, which was usually between 1:3 and 1:5. CD4 T cells were stimulated with
Staphylococcus enterotoxin B (1 g/ml; Sigma). Unless otherwise stated, the cells
were pulsed with [3H]thymidine (0.5 Ci/well; MP Biomedicals, Inc., Irvine, CA)
on day 4 and harvested on day 5 for measurement of cell lysate-associated tritium
by -scintillation counting (Perkin-Elmer, Boston, MA). All proliferation exper-
iments were performed in triplicate and reported as counts per minute.
To test MDDC supernatants for antiproliferative activity, CD4 T cells (0.6 
105 to 1  105/well) were incubated in 96-well plates with SEB for 3 days in the
presence of 100 l tissue culture medium/well, of which a maximum of 84 l was
supernatant from an overnight culture of virus or mock-infected MDDC. The
cells were then pulsed with [3H]thymidine and harvested for -scintillation the
next day. To test dependence on IFN- and IFN-, MAb to IFNAR2, IL-10R2,
and IL-28R were used at concentrations of 15, 10, and 20 g/ml, respectively.
CD4 T cells were incubated with MAb in half the final volume of medium for 1 h
at 37°C before addition to the MDDC supernatant and SEB.
Transwell cultures. Virus-exposed MDDC were placed in the top chamber of
24-well Transwell culture plates (1.4  105 cells/well in 100 l; Costar, Cam-
bridge, MA). SEB (1 g/ml) and CD4 T cells (4  105 to 7  105) treated with
MAb were incubated in 600 l of media in the lower chamber. After 4 days, the
CD4 T cells were transferred to 96-well plates (0.6  105 to 1  105/well) for
measurement of proliferation using [3H]thymidine.
Enzyme-linked immunosorbent assay (ELISA) for RSV proteins. Rabbit anti-
RSV polyclonal Abs were generated by immunizing a rabbit with UV-inactivated
sucrose gradient-purified virus at a dose equivalent to 6.0 log10 50% tissue
culture infective doses given subcutaneously four times at 3-week intervals and
then terminally bled 1 month after the last dose. Rabbit anti-RSV antisera had
a 50% plaque reduction neutralization titer of 1:11,000 when tested against the
A2 strain of RSV (not shown).
For detection of RSV proteins, 96-well plates were coated at 4°C overnight
with either MDDC supernatants or RSV standards (RPMI medium containing
serial twofold dilutions of live RSV). The sample, standard dilutions, and control
wells were washed three times with phosphate-buffered saline–0.05% Tween 20
solution and blocked with 1% bovine serum albumin in phosphate-buffered
saline–0.05% Tween 20 solution prior to incubation with rabbit polyclonal anti-
RSV. Horseradish peroxidase-conjugated goat anti-rabbit IgG and 3,3,5,5-
tetramethylbenzidin (KPL, Inc., Gaithersburg, MD) were used to reveal RSV-
derived proteins. Concentrations of RSV proteins in MDDC supernatants are
expressed in equivalents relative to the amount of protein in the standard con-
taining 1  106/ml of live RSV.
Measurements of cytokines. ELISA kits for IFN- and IFN- were purchased
from PBL Laboratories (Piscataway, NJ). All other cytokines were detected with
Luminex multiplex bead assay (Linco Research, St. Charles, MO), except IL-1,
for which the bead assay was purchased from Biosource (Camarillo, CA). The
data were analyzed using the MasterPlex QT quantitation software (MiraiBio,
Alameda, CA).
Quantitative reverse transcription-PCR (RT-PCR) for IFN-. Total cellular
RNA of virus-infected or mock-infected MDDC was isolated using RNeasy
(QIAGEN, Valencia, CA) and reverse transcribed to cDNA with Superscript II
reverse transcriptase (Invitrogen, Carlsbad, CA). Primers from SuperArray (Fre-
derick, MD) specific for IFN-1 and -actin were used for PCR amplification.
The cDNA was mixed with Brilliant SYBR green quantitative PCR (qPCR)
master mix (Stratagene, La Jolla, CA), and qPCR was performed using the
Mx3005P system (Stratagene). IFN-1 mRNA quantification was normalized
using -actin.
Biological assays for IFN- activity. Signal transduction by electrophoretic
mobility shift assay (EMSA) was used to detect activation of STAT1 by IFN- in
the HT-29 cell line transfected with the IL-28 receptor complex. The effect of
IFN- on proliferation of BWLICR2 cells (stable transfectants with hIL-28R)
was measured with the hexominidase-based chromogenic viability assay as pre-
viously described (19, 27, 29).
Statistical analysis. Differences were analyzed for statistical significance with
the Wilcoxon signed rank test using JMP software (version 5; SAS Institute, Inc.,
Cary, NC).
RESULTS
RSV infects MDDC. To determine whether RSV actively in-
fects MDDC, we exposed MDDC overnight to rgRSV. Figure 1
shows that approximately 10 to 15% of the MDDC express
green fluorescent protein, suggesting that RSV is actively tran-
scribing and probably replicating in those cells. By contrast,
CD4 T cells exposed to rgRSV did not fluoresce (data not
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shown). To determine the amounts of virus in the supernatant
after overnight incubation with MDDC, we performed plaque
assays using supernatants generated from unwashed RSV-ex-
posed MDDC. To our surprise, only 1.9% of infectious PFU
were in the supernatants after overnight incubation. In con-
trast, 25% of infectious PFU was recovered when RSV was
incubated overnight in medium alone (not shown). Further-
more, analysis of MDDC supernatants by ELISA demon-
strates that the concentration of RSV proteins after overnight
incubation (whether from live or dead virus) was 38% 	 10%
(mean 	 standard deviation [SD]) of the dose to which the
MDDC were exposed. The RSV infectious PFU and proteins
found in the MDDC supernatants may be either newly repli-
cated or due to virus that had been added to the MDDC but
had not adsorbed onto the cells. Either way, it is clear that
RSV replicates poorly in MDDC for the first 12 to 18 h of
exposure.
RSV inhibits proliferation in response to either SEB or
CMV antigens. To determine factors responsible for RSV-
induced immunosuppression, we first sought to design a sim-
plified, reproducible experimental system. We used MDDC as
antigen-presenting cells and to measure proliferation of autol-
ogous T cells in response to SEB as the primary readout for
responses and suppression. Figure 2A shows that RSV and not
influenza virus inhibits proliferation of T cells in response to
SEB. Exposure of MDDC to PIV3, another paramyxovirus,
modestly inhibited T-cell proliferation as previously reported
(54, 55). To simplify the experimental system, we mixed puri-
fied CD4 T cells (97 to 99% pure, not shown) with RSV-
exposed MDDC and found suppression to be essentially the
same (Fig. 2A). The addition of RSV directly to CD4 T cells
(in the absence of MDDC), however, did not suppress SEB-
induced proliferation (Fig. 2B). Thus, RSV-induced immuno-
suppression could readily be demonstrated in a system in which
MDDC were treated with RSV and mixed with superantigen
and T cells (either CD4 or CD8 T cells).
Since lymphocytes were harvested on day 5 after exposure to
MDCC, we sought to determine whether the immunosuppres-
sive effects could be observed earlier and to verify the appro-
priate experimental time course. Figure 3A demonstrates that
T-cell proliferation in response to CMV antigens is suppressed
as early as day 3, in a dose-dependent manner. However, max-
imal suppression was observed on day 5 (Fig. 3A and B).
FIG. 1. RSV infects MDDC. MDDC (1  106/ml) were exposed
overnight to rgRSV (multiplicity of infection of 3) and washed twice
before being examined by fluorescent microscopy. The fluorescent (A)
and bright field (B) images of the same microscopic field were photo-
graphed. The figure is representative of the results of three experi-
ments.
FIG. 2. RSV induces MDDC-mediated suppression of T-cell pro-
liferation. (A) CD4 T cells together with MDDC are sufficient to
demonstrate RSV-induced immunosuppression. MDDC were exposed
to RSV (multiplicity of infection of 2.5), influenza, or PIV3 (multiplic-
ity of infection of 3) or mock infected for 4 h before the addition of
either SEB-stimulated autologous lymphocytes or purified CD4 T
cells. The cells were pulsed with [3H]thymidine on day 4 and harvested
on day 5. Each symbol shape is one of three donors. Open symbols
indicate proliferation of T cells in a population of total lymphocytes,
and filled symbols represent purified CD4 T cells. (B) RSV does not
directly inhibit CD4 T-cell proliferation. RSV (final density, 1  106
PFU/ml) or the same volume of sucrose buffer was added to SEB-
stimulated CD4 T cells and SEB for 3 days prior to pulsing with
[3H]thymidine. The bar indicates the median of data from five donors,
each represented by a different symbol.
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Figure 3C demonstrates reproducibility of experiments in
which only CD4 T cells and MDDC were used and the neces-
sity of live RSV for maximal immunosuppression. For these,
and subsequent experiments, the MDDC were washed 4 h
after incubation with RSV to minimize any effect of RSV
carryover. Consistent with the dose response shown in Fig. 3A,
immunosuppression was diminished when exposure of MDDC
to live RSV was limited to 4 h.
Supernatants from RSV-exposed MDDC transfers immuno-
suppression. To determine whether soluble factors might be
responsible for RSV-induced immunosuppression, we exposed
MDDC to RSV, UV-RSV, or sucrose buffer (mock) for 4 h,
after which time the cells were washed and incubated overnight
before harvesting supernatant. Figures 4A and B show that
only supernatants from MDDC exposed to live RSV suppress
proliferation of CD4 T cells in response to SEB and that the
suppressive effect is dose dependent. To confirm that RSV
carryover is not responsible for this immunosuppression, we
first incubated virus with humanized MAb (1 mg/ml) against
either RSV F (fusion) protein (palivizumab), or human IgE
(omalizumab) as a control to demonstrate the former’s neu-
tralization capacity. As expected, supernatants from MDDC
exposed to RSV that was neutralized by palivizumab did not
suppress CD4 T-cell proliferation (Fig. 4C). In contrast, when
added to supernatant that was harvested from RSV-exposed
MDDC, palivizumab did not reverse immunosuppression (Fig.
4C), just as live RSV added to supernatants from mock-in-
fected MDDC did not immunosuppress (Fig. 2B). Thus, the
immunosuppressive activity transferred in supernatants from
RSV-exposed MDDC is not due to RSV itself and is more
likely due to one or more soluble factors that are MDDC
derived.
Analysis of cytokines in MDDC supernatants. To determine
which soluble factors might be responsible for immunosup-
pression, we measured levels of a number of cytokines using
multiplex bead assays. Figure 5 shows that there were no dif-
ferences in supernatant derived from RSV-, UV-RSV-, or
mock-exposed MDDC in concentrations of IL-1 or IL-1.
Consistent with previous reports (32, 46), IL-1RA levels were
high in RSV supernatants and low in UV-RSV and mock-
infected supernatants. Since we found very little IL-1 or -1,
with no differences between the conditions and since the only
known activity of IL-1RA is to block binding of IL-1/ to
IL-1R, we did not explore further an immunosuppressive role
for IL-1RA.
There were no differences in IL-10, and in all three condi-
tions,transforming growth factor 1 (TGF-1) was either very
low or undetectable (not shown). Because IL-10 and TGF-1
are known to suppress T-cell proliferation, we tested whether
addition of rIL-10 (25 ng/ml) or TGF-1 (10 ng/ml) would
suppress proliferation in our system and found that they did
not (not shown). Similarly, when we removed suppressor CD4
T cells, which secrete IL-10 and TGF-1, by magnetic bead
selection (i.e., CD25, CD4 lymphocytes), we saw no differ-
ences in SEB-induced proliferation (not shown).
Tumor necrosis factor alpha levels were highest in the su-
pernatants from RSV-infected MDDC, a difference that was
significant only when compared to mock-infected MDDC su-
pernatants. IL-12 was found at high levels in both RSV and
UV-RSV supernatant but not in supernatant from the mock-
infected MDDC. Exogenous IL-12 (2 ng/ml) or IL-2 (20 U/ml)
and anti-IL-12 (2 g/ml) also had no effect in our system (not
shown).
IFN- has been previously reported to be solely responsible
FIG. 3. RSV-induced immunosuppression is dependent on time,
dose, and live virus. (A and B) Time and dose dependency of RSV-
induced immunosuppression of CMV antigen-stimulated proliferation.
MDDC were exposed to CMV antigen (vol/vol 
 1:100) and RSV (mul-
tiplicity of infection [MOI] of 0, 0.4, 1, 2.5, 6.25, 8, and 10) for 4 h before
incubation with autologous lymphocytes. Cells were pulsed with [3H]thy-
midine at different time points for proliferation assay. The results, ex-
pressed as mean cpm 	 SD, are from one representative experiment of
three. (A) Only MOI 0, 1, 2.5, and 6.25 are shown for clarity. (B) Prolif-
eration on day 5 of each experimental condition showing dose depen-
dency at that time point. (C) Only live RSV induces immunosuppression.
MDDC were incubated with live RSV or UV-RSV, each at an MOI of 1,
or an equal volume of sucrose buffer for 4 h (mock), washed, and incu-
bated with SEB-stimulated autologous purified CD4 T cells for 4 days
before harvest on day 5 for [3H]thymidine uptake assay. The bar indicates
the median of data from 15 donors.
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for RSV-induced immunosuppression (42). We therefore mea-
sured IFN- using an ELISA that detects 12 of the 14 isoforms
and found high concentrations uniquely in the RSV-exposed
MDDC supernatants (Fig. 6A). By contrast, IFN- was unde-
tectable in any of the MDDC supernatants (data not shown).
Type III interferons, which include IFN-1, 2, and 3 (also
known as IL-29, -28A, and -28B, respectively), are expressed by
macrophages at low levels in response to RSV (58). Currently,
there are no commercially available MAbs for measurement of
IFN- by ELISA, so we used two biological assays. The first
assay system measures activation of signal transducer and ac-
tivator of transcription 1 (STAT1) induced by IFN- in a
hamster cell line that is stably transfected with a cDNA encod-
ing a chimeric receptor composed of the extracellular ligand-
binding domain of IFN-R1 (IL-28R) and the intracellular
domain of the IFN-R1 chain (27). The second assay system
measures IFN- activity by quantifying the suppression of cell
division using a chromogenic viability assay of a human lym-
phoma cell line that was engineered to express the full-length
IFN-R1 chain (19). Figures 6B and C demonstrate that only
FIG. 4. Supernatants from RSV-exposed MDDC transfer immuno-
suppressive activity. (A) Supernatants from RSV, but not UV-RSV or
mock-exposed MDDC, inhibit SEB-stimulated CD4 T-cell proliferation.
MDDC were exposed to RSV or UV-RSV or mock exposed for 4 h and
washed. Supernatants were harvested after overnight incubation and in-
cubated with SEB-stimulated CD4 T cells for 3 days prior to pulsing with
[3H]thymidine for 24 h. The bar indicates the median of data from 15
donors. (B) Inhibitory effect of RSV-exposed MDDC supernatants decreases
with dilution. Means and SD of results from one representative experiment
of three are shown. (C) RSV or RSV F proteins in the supernatants are
not responsible for immunosuppression of CD4 T cells. RSV or superna-
tants from RSV- or mock-exposed MDDC were incubated with palivi-
zumab or omalizumab (1-mg/ml final concentration) for 1 h at 37°C before
addition to MDDC or SEB-stimulated CD4 T cells, respectively. The
data, expressed as mean counts per minute 	 SD, are cumulative from
three donors. Filled bars, MAb added directly to RSV prior to addition of
virus to MDDC; open bars, MAb added to MDDC supernatants prior to
mixing with CD4 T cells; a-RSV F, anti-RSV F protein; a-hIgE, anti-hIgE.
FIG. 5. RSV induces secretion of tumor necrosis factor alpha, IL-
12, and IL-1RA, but not IL-1, IL-1, or IL-10, from MDDC. Data
from 14 donors are shown. The upper and lower error bars indicate the
90th and 10th percentiles, respectively; the borders of each box indi-
cate the 75th and 25th percentiles; the bar within the box indicates the
median, and the filled circles show the highest (and in the case of
IL-1RA, the lowest) data points of each set.
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supernatants from RSV-exposed MDDC contained apprecia-
ble levels of IFN-, The concentration of type I IFN in the
supernatants is estimated to be between 1 to 5 ng/ml and 5 to
20 ng/ml, based on the specific activity of rIFN- in the EMSA
and proliferation assays, respectively. Expression of IFN- by
RSV-infected MDDC was confirmed by qRT-PCR (Fig. 6D).
IFN- and IFN- contribute to the inhibitory effect of RSV-
exposed MDDC supernatants. We then asked whether IFN-
and IFN- mediate RSV-induced immunosuppression by
treating the CD4 T cells with neutralizing MAb to IFNAR2
(CD118), one of the two chains of IFN-/ receptor, and
MAbs to both of the members of the IFN- receptor complex,
IL-10R2 and IL-28R. Two experimental systems were used:
transfer of supernatants and Transwell cultures by placing
MDDC in the top chamber and the CD4 T cells in the bottom
chamber for the first 3 days of incubation. RSV-induced im-
munosuppression in the Transwell system is shown in Fig. 7A.
While each of the MAbs alone may have a modest effect, the
combination of either anti-IFNAR2 with anti-IL10R2 or with
anti-IL28R substantially abrogated suppression after transfer
FIG. 6. RSV induces secretion of IFN- and IFN- from MDDC
supernatants. (A) IFN- protein is expressed in response to live RSV.
Data from 15 donors are shown. (B and C) IFN- activity is expressed
in response to live RSV. (B) Supernatants from RSV-infected MDDC
inhibit proliferation of BWLICR2 cells. The parent line BW5147 was
unaffected by any of the supernatants (not shown). The figure shown is
representative of data from five donors. (C) HT-29 cells transfected
with the IL-28 receptor complex were exposed to MDDC superna-
tants, harvested, and analyzed by EMSA for activation of STAT1 in
response to supernatants from MDDC that were exposed to RSV
(lanes a), UV RSV (lanes b), or mock infection (lanes c). Lanes 5 to
8 are nuclear extracts from transfected HT-29 cells treated with
rhIFN-1 at 500, 50, 5, and 0.5 ng/ml, respectively. , present; ,
absent. (D) IFN-1 mRNA is expressed in response to live RSV. RNA
harvested from MDDC was analyzed for expression of the gene for
IFN-1 by qRT-PCR and shown as a ratio to expression of the gene for
-actin. Data from 16 donors are shown.
FIG. 7. IFN- and IFN- contribute to the inhibitory effect of
RSV-exposed MDDC supernatants. (A) RSV-induced immunosup-
pression can be demonstrated with the Transwell system. MDDC were
exposed to mock, live, or UV-inactivated RSV for 4 h, washed, and
placed in the top chamber of Transwell plates (pore size, 0.4 m). The
bottom chamber contained autologous purified CD4 T cells stimulated
with SEB (1 g/ml). Each symbol represents a different donor.
(B) Neutralizing MAbs to IFN- and IFN- receptors together sub-
stantially reverse the inhibitory effect of RSV-exposed MDDC super-
natant (top) or in the Transwell system (5-m pore size, bottom). Each
symbol represents a different donor. Since an n of 6 is required for the
Wilcoxon signed-rank test, the data from the top and bottom plots
were pooled for additional statistical analysis. -IFNAR2, anti-
IFNAR2; -IL10R2, anti-IL10R2; -IL28R, anti-IL28R; ,
present; , absent.
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of supernatants and in the Transwell system (Fig. 7B, top and
bottom, respectively).
DISCUSSION
We explored the mechanism of RSV-induced immunosup-
pression by first simplifying the experimental system to MDDC
and autologous CD4 T cells, thus eliminating interactions with
CD8 T cells, B cells, and NK cells. Our approach was similar to
that of Bartz and colleagues (5), who used cord blood CD4 T
cells, which are all naive, and cord blood CD34 cells to derive
dendritic cells (DC). In that report, treatment of DC with RSV
suppressed IFN- secretion but not proliferation in response
to superantigen. Preliminarily, we have seen no difference in
suppression by RSV-infected MDDC of sorted naive versus
memory CD4 T cells (B. Chi and R. L. Rabin, unpublished
data), but the difference in the source of DC, age of donor, or
both may easily account for the difference in functional sup-
pression between the two reports.
Since RSV had no direct effect on CD4 T cells (Fig. 2B), we
could concentrate on MDDC as a source of suppressive activ-
ity, and since suppressive activity could be transferred with
supernatants from MDDC (Fig. 4A), we turned our attention
toward soluble factors secreted by them. And since suppres-
sion of T-cell proliferation is induced only with infection of
MDDC by live RSV (Fig. 3C and 4A), we ruled out the pos-
sibility that live RSV directly suppresses CD4 T-cell prolifer-
ation by demonstrating, first, that CD4 T-cell suppression was
unaffected by addition of palivizumab to supernatants from
RSV-infected MDDC (Fig. 4C) and, second, that direct addi-
tion of live (Fig. 2B) or UV-killed RSV (not shown) to CD4 T
cells did not suppress proliferation in response to SEB. Fur-
thermore, consistent with a previous report using a similar
experimental system (5), live RSV, and RSV-derived protein
levels in harvested supernatants actually diminished. However,
there are some obvious limitations to these experiments that
must be acknowledged. First, it is not known if palivizumab
blocks virus or F binding to cells or if palivizumab neutraliza-
tion is mediated at a postbinding step. Because palivizumab
specifically interacts with a single epitope within the F1 region,
it would not be expected to block virus attachment mediated by
the F2 portion of the fusion glycoprotein or inhibit interactions
with the G glycoprotein. Second, these experiments do not rule
out the possibility that RSV-secreted G glycoprotein may play
a role in T-cell suppression. It is apparent, however, that type
I and III IFN-mediated suppression is distinct from inhibition
of NF-B mediated by RSV-soluble G glycoprotein, the latter
of which is not dependent on live virus (1, 41). Taken together,
it appeared unlikely that RSV virions or proteins directly sup-
press T cells in our experiments; thus, we focused on MDDC-
derived soluble factors.
One such factor that has been held responsible for RSV-
induced immunosuppression is IL-1RA (32, 46). We found
high levels of IL-1RA in the MDDC supernatants but very
little IL-1 and IL-1, suggesting that IL-1RA probably has no
role in this context. Similarly, TGF-1 and IL-10 are immuno-
suppressive cytokines that were ruled out because TGF-1 was
undetectable in the MDDC supernatants (not shown) and
IL-10 levels were similar in all experimental conditions. Fur-
thermore, neither addition of rhTGF-1 or rhIL-10 to control
MDDC supernatants nor exclusion of suppressor CD4 T cells
(CD4, CD25 lymphocytes), an important source of TGF-1
and IL-10 blocked RSV-induced suppression (not shown).
IL-12 enhances T-cell proliferation (61) and was induced by
RSV and UV-RSV. However, neither neutralization with anti-
IL-12 MAb nor supplementation with rhIL-12 blocked RSV-
induced immunosuppression (not shown). Similarly, IFN-,
classically a product of T and NK cells, can be also expressed
by DC (60) and may be immunosuppressive (12, 37). Consis-
tent with a previous report (39), neutralizing MAb to IFN-
enhanced, rather than diminished, suppression of proliferation
(data not shown).
IFN- levels were elevated in supernatants of MDDC ex-
posed to live RSV (Fig. 6A). Similarly, RSV induces expres-
sion of IFN- in monocyte-derived macrophages (58) and
MDDC (Fig. 6B, C, and D). IFN-1, IFN-2, and IFN-3
comprise the newly described type III IFN, which may be
expressed by a variety of cells, including plasmacytoid DC,
MDDC, and macrophages in response to a variety of stimuli,
including viruses (13). The receptor for the type III IFN con-
sists of the ligand-binding chain, IL-28R, and the accessory
receptor chain, IL-10R2 (27, 53). IL-28R is unique to the type
III IFN, but IL-10R2 also dimerizes with IL-10R1, IL-22R, and
IL-26R to signal in response to their respective cytokines (for
a review, see reference 18). In contrast to these three IL-10
family members, STAT1 and STAT2 primarily transduce sig-
nals through the IFN-R complex, as they do for the IFN-/
and - receptors (16, 38).
To determine whether IFN- and IFN- contribute to RSV-
induced immunosuppression, we used MAb to one of the two
chains of IFN-/ receptor, IFNAR2 (CD118), and to the two
chains of the IFN-R complex, IL-10R2 and IL-28R, to block
receptor binding. In contrast to a previous report that IFN-
is solely responsible for RSV immunosuppression (42), anti-
IFNAR2 only modestly diminished immunosuppression (Fig.
7). Similarly, anti-IL10R2 or anti-IL-28R was relatively inef-
fective. But when anti-IFNAR2 was combined with either anti-
IL-10R2 or anti-IL-28R, the level of suppression was substan-
tially decreased, thus demonstrating synergism between the
two IFN. Since type I and III IFN both signal through STAT1
and STAT2, the two IFN might synergize by surpassing a
threshold of signaling that neither could achieve alone. On the
other hand, the two IFN may qualitatively signal such that only
when present together are unique pathways activated or
blocked. To our knowledge, this is the first report that type III
IFN affect T-cell function.
The dependence of RSV-induced immunosuppression on
type I and III IFN is paradoxical considering that (i) IFN are
expressed in response to a variety of stimuli, including many
other viruses that are not associated with T-cell suppression;
(ii) plasmacytoid DC may express 100-fold as much IFN- as
MDDC and yet are critical to the ultimate antiviral adaptive
response (56); and (iii) type I IFN prevent activation-induced
death of murine T cells in vitro after stimulation with super-
antigen in vivo (31). The emerging story, however, is that the
effects of type I IFN on CD4 T cells are dependent on the
context in which they are exposed. For example, Dondi and
colleagues showed that, in the context of TcR stimulation,
exogenous IFN- is antiapoptotic early and proapoptotic later
(17). Most relevant to our report, entry into the cell cycle was
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delayed when TcR stimulation followed IFN- exposure (17),
apparently due to sequestration by the type I IFN receptor
complex of CD45, Lck, and ZAP-70 (40), all of which are
necessary to initiate, but not to sustain, cellular responses to
stimulation through the TcR (11). Similarly, high concentra-
tions of IFN- cause STAT2 to associate with STAT6 and
enhance signaling through the IL-4 receptor for the first 6 h of
exposure; thereafter, IFN- inhibits IL-4 responses (20). Fi-
nally, IFN- may activate STAT4 (36), which while insufficient
to induce Th1 differentiation (7), may enhance it when induced
by IL-12. It is likely that the contextual complexity of T-cell
responses to IFN- is only increased by the addition of type III
IFN into the equation. The combination of type I and type III
IFN could favor signaling through pathways that preferentially
activate antiproliferative effects of IFN rather than those path-
ways that mediate the antiviral effects.
RSV has a number of strategies to minimize its vulnerability
to IFN-. The products of the NS1 and NS2 genes inhibit the
upstream expression of IFN- (8, 25, 47, 58) by suppressing
activation and nuclear translocation of interferon regulatory
factor 3 (8, 59) and block downstream responses by decreasing
STAT2 levels (2, 44). Since cellular responses to IFN- are
complex and dependent upon context, it is reasonable to sus-
pect that RSV may have achieved the fine balance of impairing
antiviral properties of IFN- while its suppressive activity may
persist. Proliferation is not likely the only impaired T-cell re-
sponse. For example, since IL-4 attenuates CD8 T-cell cyto-
lytic function (3, 4), cytolysis may be further impaired when
IFN- enhances signaling in response to IL-4 (20). This is but
one potential mechanism by which RSV may deviate T-cell
responses in ways that are highly relevant to infection with
RSV and its sequelae, including childhood wheezing and
asthma.
Conversely, suppression of T-cell responses during RSV in-
fection may actually offer some benefit to the host. Our model
system uses MDDC and autologous CD4 T cells derived from
healthy, young adult donors, a population in which RSV lower
respiratory tract disease is rare (22). Since the host inflamma-
tory response contributes significantly to lower respiratory dis-
ease (34), diminished or absent suppressive activity in infants 2
to 6 months of age (22) and the infirm elderly (21) may account
for their susceptibility to RSV pneumonia.
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